This study confirms the preliminary reports that
Duogastrone effectively controls the symptoms of duodenal ulceration and appears to hasten healing. In a double-blind trial, 14 patients with active
duodenal ulcers were treated with
Duogastrone capsules, one four times daily, half-an-hour before meals, while a comparable control group of 14 patients was treated similarly with a placebo containing
magnesium trisilicate. Treatment continued for 12 weeks with clinical assessments fortnightly and a radiological assessment at the start and at the end of treatment. Only one of the 14 patients receiving
Duogastrone did not respond. The remaining 13 showed marked clinical improvement with complete relief of
pain and ceased to require supplementary
antacids. Radiological evidence of healing or marked improvement was seen in eight of the 14 patients. None of the patients in the control group showed any marked improvement either of
pain or tenderness and no changes were detectable by radiology. Patients in this group showed no reduction in their demand for supplementary
antacids to relieve symptoms. No significant side effects were encountered. It is concluded that
Duogastrone accelerates the healing of
duodenal ulcer in ambulant patients and affords a much greater and more rapid relief of symptoms than does
magnesium trisilicate.